A recent report posted on FoxNews.com noted that researchers from the Institute of Cancer Research in London have found a new use for previously developed breast and ovarian cancer drugs in the treatment of lung cancer. The study, published in the journal Oncogene, found that the poly ADP ribose polymerase (PARP) drug could be of use in treating 50 percent of non-small cell lung cancer tumors.
PARP drugs are currently used to treat women who have breast and ovarian cancers linked to BRCA1 or BRCA2 gene mutations. The drugs simultaneously target two types of DNA repair systems to kill these types of cancer cells and not kill surrounding healthy cells. Researchers believe that the drugs can be repurposed to create a similar effect in lung cancer tumors and hope to find better methods to successfully treat lung cancers. Clinical trials to test the PARP inhibitors on lung cancer patients are now being planned.
At Blume Forte, we understand that even the most effective cancer treatments cannot help a patient if he or she is improperly or untimely diagnosed by a healthcare professional. If you have suffered serious health complications due to a failure to properly or timely diagnose breast, lung or any cancer, contact our legal team at 973-845-4421. The information you receive can help you better understand your potential options.